Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting
  • Home
  • Signaling Pathways

Signaling Pathways

9 Items

per page
  1. Regorafenib
    A8236 Regorafenib
     4 Citation
    Target: Raf|VEGFR|PDGFR|c-Kit|RET
    Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1
      ≥25.04 mg/mL
  2. AD57 (hydrochloride)
    C3080 AD57 (hydrochloride)
    Summary: polypharmacological cancer therapeutic that inhibits RET.
      ≤5 mg/mL
  3. RPI-1
    C4239 RPI-1
    Summary: ATP-dependent RET kinase inhibitor
      ≤1 mg/mL
  4. TG101209
    A4145 TG101209
    Summary: JAK2/3 inhibitor
      ≥25.5 mg/mL
  5. Danusertib (PHA-739358)
    A4116 Danusertib (PHA-739358)
     2 Citation
    Target: Aurora Kinases
    Summary: Pan-aurora kinase inhibitor
      ≥23.75 mg/mL
  6. Amuvatinib (MP-470, HPK 56)
    A4237 Amuvatinib (MP-470, HPK 56)
    Summary: Tyrosine kinase inhibitor
      ≥22.4 mg/mL
  7. Regorafenib hydrochloride
    A3750 Regorafenib hydrochloride
    Target: Raf|VEGFR|PDGFR|c-Kit|c-RET
    Summary: Tyrosine kinase inhibitor
      ≥25.95 mg/mL
  8. Regorafenib monohydrate
    A3751 Regorafenib monohydrate
    Summary: Tyrosine kinase inhibitor
      ≥25.05 mg/mL
  9. SU5416
    A3847 SU5416
    Target: VEGFR
    Summary: VEGF receptor inhibitor and AHR agonist
      insoluble in EtOH; insoluble in H2O; ≥11.9 mg/mL

9 Items

per page